Anlon Healthcare Limited reported a standalone net profit of ₹479.71 lakh for the quarter ended June 30, 2026, marking a 27% decline from ₹354.69 lakh in the corresponding period of FY25. The drop in profitability was driven by a 7% contraction in total income from operations, which fell to ₹3097.56 lakh from ₹3329.72 lakh in Q1FY25. Consolidated net profit also eased to ₹828.14 lakh from ₹354.69 lakh previously, though the consolidated revenue base expanded significantly to ₹8756.27 lakh compared to ₹3329.72 lakh in the prior year quarter, suggesting potential structural changes in the group’s reporting scope or acquisitions.

The filing, submitted under Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was certified by Managing Director Punitkumar Rasadia. The results were published via newspaper advertisement in Financial Express on August 01, 2026, and filed with both BSE and NSE. No dividend was declared for the quarter.

Financial Performance Overview

Note: Percentage changes calculated based on absolute values provided in the source document.

While standalone pre-tax profits rose 18% to ₹590.37 lakh from ₹500.41 lakh, the after-tax profit growth of 35% was more pronounced, indicating favorable tax adjustments or one-time credits not detailed in the extract. However, the broader context shows a sequential decline from the previous quarter’s standalone PAT of ₹979.20 lakh (Q4FY25), highlighting volatility in recent performance.

What the Numbers Show

The divergence between standalone and consolidated figures warrants attention. While standalone operations saw a slight dip in revenue, consolidated income nearly tripled year-on-year to ₹8756.27 lakh. This suggests that Anlon Healthcare may have integrated new subsidiaries or changed its consolidation methodology during FY26. Investors should monitor future disclosures for clarity on whether this consolidated base is sustainable or a one-off adjustment. Additionally, the flat EPS at ₹0.09 per share (basic) despite higher consolidated profits points to a significant increase in share capital—from ₹3985.15 lakh in Q1FY25 to ₹10630.30 lakh in Q1FY26—likely due to a face value reduction from ₹10 to ₹2 per share, which dilutes per-share metrics without changing overall equity value.

Anlon Healthcare Limited will host an earnings conference call on August 6, 2026, to discuss its Q1FY27 audited financial results. The call provides investors and analysts with an opportunity to review the company’s performance for the quarter ended June 30, 2026. Management has clarified that the discussion will be strictly limited to publicly available documents, ensuring no unpublished price-sensitive information (UPSI) is shared during the interaction.

The company issued the invitation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on July 31, 2026. This regulatory filing ensures transparency and compliance with listing norms regarding investor communication.

Key Meeting Details

The earnings call is scheduled for Thursday, August 6, 2026, at 4:00 PM IST. The session will be conducted virtually via Zoom, requiring prior registration. ConfideLeap Partners is managing the logistics for the event.

Management Participation

Punit Rasadia, Chairman and Managing Director of Anlon Healthcare Limited, will lead the management team during the call. As the primary executive spokesperson, Rasadia will address queries related to the company’s operational and financial performance for the quarter. His DIN is 06696258.

Regulatory and Compliance Notes

The company emphasized that all statements made during the call will be based on existing public disclosures. Investors are advised that forward-looking statements may be included, which are subject to risks and uncertainties such as changes in the economic environment. Actual results may differ from those implied in such statements. The company disclaims responsibility for actions taken based on these forward-looking projections.